Center for Advanced Gerotherapeutics, Cedars-Sinai
Academic
About
The Center for Advanced Gerotherapeutics at Cedars-Sinai Medical Center, Los Angeles, was launched with the recruitment of James Kirkland from Mayo Clinic in 2024, with Tamar Tchkonia as co-director. It develops and tests drugs that target basic ageing processes, chiefly cellular senescence, including senolytics such as dasatinib plus quercetin and fisetin, and senomorphics. Its Facility for Geroscience Analyses, led by Tchkonia, measures senescence, epigenetic and mitochondrial biomarkers in samples from Cedars-Sinai studies and the NIH-funded Translational Geroscience Network, which Kirkland leads as a principal investigator. The centre sits alongside Cedars-Sinai's Center for Translational Geroscience and Diabetes and Aging Center, and supplies an Advanced Gerotherapeutics core to the Los Angeles Pepper Older Americans Independence Center. Cedars-Sinai says it plans senolytic trials in treatment-resistant cancers, organ preservation for transplant, and fibrotic diseases.
Rating breakdown
Aggregate 62/100 · rank #9 in the academic & non-profit table full ratings →
Expand a signal to see what contributes to it.
Publications73
- James Kirkland — h-index 125 source ↗
- A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease (Millar et al., eBioMedicine 2025; dasatinib plus quercetin) ↗
- Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical function (Wang et al., Cell Metabolism 2024) ↗
- Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice (Suda et al., Cell Metabolism 2025) ↗
- Senescent cell transplantation into the skin induces age-related peripheral dysfunction and cognitive decline (Franco et al., Aging Cell 2025) ↗
- Cellular senescence and the senescent secretory phenotype: therapeutic opportunities (Tchkonia, Kirkland et al., Journal of Clinical Investigation; foundational senotherapeutics review by the director and co-director, conducted at Mayo Clinic) ↗
Discovery78
Trials from ClinicalTrials.gov (this org as lead sponsor), matched to aging by their condition or intervention.
- The Achilles' heel of senescent cells: from transcriptome to senolytic drugs (Zhu et al.; first identification of senolytics, dasatinib + quercetin, by the center's director and co-director at Mayo Clinic; Aging Cell) ↗
- Senolytics decrease senescent cells in humans: first-in-human open-label pilot of dasatinib plus quercetin in diabetic kidney disease (Hickson et al., EBioMedicine; foundational human senolytics study led by Kirkland/Tchkonia at Mayo Clinic) ↗
- Senolytics in idiopathic pulmonary fibrosis: first-in-human open-label pilot study (Justice et al., EBioMedicine; foundational human senolytics study associated with Kirkland/Tchkonia) ↗
- Single-nuclei RNA-seq to map adipose cellular populations and senescent cells in older subjects (Cedars-Sinai geroscience trial, lead sponsor Cedars-Sinai Medical Center, PI Nicolas Musi), NCT05653258 ↗
Fundraising92
Grants of the organisation's listed people, name-matched via NIH RePORTER ↗.
- Tamar Tchkonia: Translational Geroscience Network · USD 796K · National Institute on Aging 7R33AG061456-07
- James Kirkland: Translational Geroscience Network · USD 702K · National Institute on Aging 5R33AG061456-08
- Tamar Tchkonia: Translational Geroscience Network · USD 702K · National Institute on Aging 5R33AG061456-08
- James Kirkland: Resource Core 1 (RC1) Advanced Gerotherapeutics · USD 319K · National Institute on Aging 5P30AG094848-02
Education0
No public-education signals recorded.
Key outputs
- publication A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease (Millar et al., eBioMedicine 2025; dasatinib plus quercetin) ↗ 2025
- publication Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical function (Wang et al., Cell Metabolism 2024) ↗ 2024
- publication Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice (Suda et al., Cell Metabolism 2025) ↗ 2025
- publication Senescent cell transplantation into the skin induces age-related peripheral dysfunction and cognitive decline (Franco et al., Aging Cell 2025) ↗ 2025
- other Facility for Geroscience Analyses: biomarker panel (about 100 protein, nucleotide and senescent-cell tests) for geroscience trials, including the Translational Geroscience Network ↗
- publication Cellular senescence and the senescent secretory phenotype: therapeutic opportunities (Tchkonia, Kirkland et al., Journal of Clinical Investigation; foundational senotherapeutics review by the director and co-director, conducted at Mayo Clinic) ↗ 2013
- discovery The Achilles' heel of senescent cells: from transcriptome to senolytic drugs (Zhu et al.; first identification of senolytics, dasatinib + quercetin, by the center's director and co-director at Mayo Clinic; Aging Cell) ↗ 2015
- clinical trial Senolytics decrease senescent cells in humans: first-in-human open-label pilot of dasatinib plus quercetin in diabetic kidney disease (Hickson et al., EBioMedicine; foundational human senolytics study led by Kirkland/Tchkonia at Mayo Clinic) ↗ 2019
- clinical trial Senolytics in idiopathic pulmonary fibrosis: first-in-human open-label pilot study (Justice et al., EBioMedicine; foundational human senolytics study associated with Kirkland/Tchkonia) ↗ 2019
- clinical trial Single-nuclei RNA-seq to map adipose cellular populations and senescent cells in older subjects (Cedars-Sinai geroscience trial, lead sponsor Cedars-Sinai Medical Center, PI Nicolas Musi), NCT05653258 ↗ 2022
Investment & funding
| Date | Type | Amount | Detail | Counterparties |
|---|---|---|---|---|
| 2025 | grant | USD 796K | NIH RePORTER publicly disclosed the FY2025 award to Cedars-Sinai for R33AG061456, Translational Geroscience Network (PIs Kirkland, Kritchevsky, Kuchel, Tchkonia) | National Institute on Aging (NIH) |
| 2025-09 | grant | USD 359K | NIH RePORTER publicly disclosed the FY2025 award for Resource Core 1 (Advanced Gerotherapeutics) of the Los Angeles Claude D. Pepper Older Americans Independence Center, P30AG094848 (core lead Kirkland) | National Institute on Aging (NIH) |
Key people
James KirklandDirector, Center for Advanced Gerotherapeutics (since 15 Jul 2024); Professor of MedicineTamar TchkoniaCo-Director, Center for Advanced Gerotherapeutics; leads the Facility for Geroscience AnalysesSara E. EspinozaDirector, Cedars-Sinai Center for Translational Geroscience; Medical Director, Healthspan Clinic; collaborates with the Center for Advanced Gerotherapeutics on the shared geroscience enterpriseNicolas MusiDirector, Cedars-Sinai Diabetes and Aging Center; leads Cedars-Sinai geroscience clinical trials; collaborates with the Center for Advanced Gerotherapeutics
Research fields
Links
Sources
- https://www.cedars-sinai.org/stories-and-insights/innovation-and-research/the-future-of-aging-research
- https://www.cedars-sinai.org/newsroom/time-the-scientific-search-for-youth/
- https://researchers.cedars-sinai.edu/James.Kirkland
- https://researchers.cedars-sinai.edu/Tamar.Tchkonia
- https://reporter.nih.gov/project-details/11330785
- https://reporter.nih.gov/project-details/11213783
- https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=AFF%3A%22Advanced%20Gerotherapeutics%22
- https://doi.org/10.1016/j.ebiom.2025.105612
- https://doi.org/10.1016/j.cmet.2024.07.006
- https://doi.org/10.1172/JCI64098
- https://doi.org/10.1111/acel.12344
- https://doi.org/10.1016/j.ebiom.2019.08.069
- https://doi.org/10.1016/j.ebiom.2018.12.052
- https://clinicaltrials.gov/study/NCT05653258